Identification of 6‐oxo‐prostaglandin E1 as a naturally occurring prostanoid generated by rat lung
Open Access
- 1 February 1986
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 87 (2), 327-335
- https://doi.org/10.1111/j.1476-5381.1986.tb10821.x
Abstract
1 The spontaneous release of prostanoids from rat isolated perfused lungs was studied after acid/organic extraction of perfusates by bioassay, radioimmunoassay, thin layer and high performance liquid chromatographic methods and by gas chromatography-negative ion mass spectroscopy (g.c.-n.i.m.s.). 2 An acid/organic extractable anti-aggregatory vasodilator prostaglandin which inhibited the twitch response of the field-stimulated guinea-pig vas deferens was released from the Krebs-perfused rat lung in nanogram amounts similar to those of other detected prostanoids. Parallel biological assay suggested that this prostaglandin had very closely similar pharmacological activity to authentic 6-oxo-prostaglandin E1 (6-oxo-PGE1), a metabolite of prostacyclin (PGI2) generated by the action of the enzyme 9-hydroxyprostaglandin dehydrogenase (9-PGDH). 3 6-oxo-PGE1 was identified conclusively in extracts of rat lung perfusate by thin layer chromatography, high performance liquid chromatography and g.c./m.s. combined with bioassay (inhibition of platelet aggregation), and its covalent structure was defined by g.c. negative ion chemical ionization mass spectroscopy. 4 The rank order of spontaneous release of prostanoids (measured by radioimmunoassay) from the perfused rat lung was 6-oxo-PGF1α > thromboxane B2 (TXB2) > PGE2 > 6-oxo-PGE1 (measured biologically) > PGF2α. Release of all five prostanoids was inhibited by indomethacin, but only that of 6-oxo-PGE1 was inhibited by naringenin. 5 Rat lung 100,000 g cytosolic supernatants contained 9-PGDH activity capable of removing 9β-tritium from labelled prostacyclin and forming an acid/organic extractable 6-oxo-PGE1-like anti-aggregatory substance. This 9-PGDH activity was inhibited by naringenin (IC50 10.3 μM). 6 The relevance of these findings to the possible physiological role of 6-OXO-PGE1 in the lung is discussed, and we propose that 6-oxo-PGE1 should be accorded the status of a physiologically relevant, naturally occurring metabolite of arachidonic acid.This publication has 31 references indexed in Scilit:
- Age-dependent changes in the synthesis and catabolism of 6 OXO PGE1 and other prostanoids by the rat kidney in vitroBiochemical Pharmacology, 1985
- Arachidonic acid and prostaglandin endoperoxide metabolism in isolated rabbit and coronary microvessels and isolated and cultivated coronary microvessel endothelial cells.Journal of Clinical Investigation, 1983
- The effect of some flavone drugs on the conversion of prostacyclin to 6-oxoprostaglandin E1Biochemical Pharmacology, 1983
- 6-Keto-Prostaglandin E1: Its Formation by Platelets from Prostacyclin and Resistance to Pulmonary DegradationPharmacology, 1983
- Analysis of picomolar concentrations of 6-oxo-prostaglandin F1 in biological fluidsJournal of Chromatography A, 1982
- Measurement of circulating prostacyclinNature, 1981
- 6-keto PGE1: a possible metabolite of prostacyclin having platelet antiaggregatory effects.Hypertension, 1980
- Hepatic metabolism of prostacyclin (PGI2) in the rabbit: Formation of a potent novel inhibitor of platelet aggregationBiochemical and Biophysical Research Communications, 1980
- Hypotensive and renovascular actions of 6-keto-prostaglandin E1, a metabolite of prostacyclinEuropean Journal of Pharmacology, 1979